Client services:(888)700-7110

Investor Overview

  1. Chart
  2. Quote
Stock price graph
- 0.01
Day High:
Day Low:
3:55 PM ET on Jul 31, 2014

Delayed at least 20 minutes.
Provided by eSignal.

About Response Genetics, Inc.

Response Genetics, Inc. (“RGI”) (NASDAQ:RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies which enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and is located in Los Angeles, California. For more information, please visit

View all »   RSSRecent Releases

Jun 16, 2014
Response Genetics Launches New Test for Cancer Immunotherapy Drug Development

Jun 12, 2014
FDA-Cleared, Medicare-Reimbursed, ResponseDX: Tissue of Origin(TM) Test Added to National Institute of Health's (NIH) Genetic Testing Registry